Table 1 Anti-amyloid therapy US FDA–approval status
From: Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Name | Synonyms | Company | Target | Therapy type | Approval status |
|---|---|---|---|---|---|
Aduhelm | Aducanumab, BIIB037 | Biogen, Neurimmune | Aβ aggregates | Immunotherapy (passive) | Accelerated approval |
Leqembi | Lecanemab-irmb, BAN2401 | BioArctic AB, Biogen, Eisai | Aβ protofibrils | Immunotherapy (passive) | Full approval |
Donanemab | N3pG-Aβ Monoclonal Antibody, LY3002813 | Eli Lilly & Co | Aβ aggregates | Immunotherapy (passive) | Application for full approval |